Developing expression systems for pharmaceutical products
Today we’re pleased to announce the completion of the pilot phase of our previously announced partnership with Novo Nordisk!
With the pilot phase completed and the first milestone achieved, we will now work with Novo Nordisk to move into the development phase to work towards making a more effective production process. Achievement of the first milestone included extensive modification and testing of a microbial expression system to understand the impact of the modifications on key performance parameters.
“Ginkgo’s achievement of the first milestone has both excited and inspired us, giving us the confidence to move into the next phase of this ambitious project,” said Brian Vandahl, Senior Vice President, Global Research Technologies at Novo Nordisk. “This progress is a strong indicator of the potential we have to engineer biological systems that will expand the chemical space of biological medicines.”
We’re excited to continue our work with Novo Nordisk to help provide innovative treatment options for patients with diabetes, obesity, and other serious chronic diseases. The next phase of this project will build on our existing microbial design, engineering, and phenotyping expertise while expanding Ginkgo’s capabilities in genome-scale design and engineering. We believe this work will enable us to support even more pharmaceutical products, helping to achieve better outcomes for patients.
Find the full press release here along with all of the latest news from the Ginkgo team.
